How do TCAs differ from SNRIs in their pain indication and side-effect profiles?

• A. TCAs have anticholinergic and cardiotoxic risks; SNRIs have hypertension and tachycardia; both can help neuropathic pain
• B. SNRIs have anticholinergic effects and cardiotoxic risks
• C. Both are safer and more tolerable than TCAs
• D. TCAs are contraindicated in neuropathic pain

Answer: (D)

The main idea is that both TCAs and SNRIs can be used for neuropathic pain, but their adverse effect profiles differ in ways that influence choosing one over the other. TCAs tend to have prominent anticholinergic effects—dry mouth, constipation, blurred vision, urinary retention—and they carry cardiotoxic risks, especially in overdose, which can limit use in older patients or those with heart disease. SNRIs, on the other hand, are more likely to raise blood pressure and pulse (hypertension, tachycardia) and have fewer anticholinergic effects, so their tolerability is different. Both drug classes can provide analgesia in neuropathic pain by boosting monoamines in the spinal cord and brain, but TCAs pose more anticholinergic and cardiotoxic concerns, while SNRIs bring cardiovascular effects into play.

That’s why the statement describing TCAs as having anticholinergic and cardiotoxic risks and SNRIs as associated with hypertension and tachycardia, with both able to help neuropathic pain, best captures the distinction. The idea that TCAs are contraindicated in neuropathic pain is not correct—these agents are commonly used for that indication—so that choice isn’t accurate. Similarly, attributing anticholinergic effects to SNRIs or claiming both are uniformly safer than TCAs overlooks important safety differences.